Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novartis buys rights to Google's 'smart lens' technology

Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia

Google Novartis Alcon smart lens 

Novartis has licensed Google's new 'smart lens' technology in a deal that will see its eye health unit Alcon work with the technology company develop new types of contact lenses.  

The technology combines non-invasive sensors, microchips and other miniaturised electronics which are so small they resemble bits of glitter embedded within contact lenses.  

Google revealed earlier this year it was testing smart contact lens that can measure diabetes patients' glucose levels via their tears and connect wirelessly with a mobile device to store this information.  

Applying the minimally invasive technology within the diabetes arena to reduce the burden of regular blood glucose tests is one of the key areas of interest for Novartis in its new deal with Google.  

The other is to help people with presbyopia – age-related long-sightedness that makes it more difficult to focus on objects that are near.  

Novartis hopes people with presbyopia who can no longer read without glasses could benefit from a smart lens, either in the form of an accommodative contact lens or an intraocular lens, to help restore the eye's natural autofocus as part of refractive cataract treatment.  

Google Novartis Alcon smart lens health 

Beyond these two areas other applications may yet be forthcoming and Novartis has licensed 'all ocular medical uses' of Google smart lens technology.  

Novartis CEO Joseph Jimenez said: "We are looking forward to working with Google to bring together their advanced technology and our extensive knowledge of biology to meet unmet medical needs.  

“This is a key step for us to go beyond the confines of traditional disease management, starting with the eye."  

For Jimenez's company the deal between Alcon and the Google[x] team - which is tasked with finding new solutions to major global problems - fits into Novartis' plans to “evolve technology to manage human diseases and conditions”, where its initiatives include a recently tie-up with quantified self firm TicTrac.  

Sergey Brin, co-founder of Google, said: "Our dream is to use the latest technology in the miniaturisation of electronics to help improve the quality of life for millions of people. We are very excited to work with Novartis to make this dream come true."  

The agreement, which remains subject to anti-trust approvals, would also allow Google to avoid having to deal with some of the "painful regulation" Brin sees in the health tech space.

15th July 2014

From: Sales, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics